The division bench of Justice GS Patel and Justice Dr Neela Gokhale has directed the capital markets regulator to file its response by July 20 in the matter, and has adjourned the case to August 2 for further hearing.
While the headline valuation may not look very expensive, it could be misleading due to the large contribution of banks to overall profits of Nifty. A sectoral break-up of net profits of Nifty50 index across shows that the contribution of banks has gone up from 21% in 2022 to 27% in 2023.
The companies that have improved their debt repayment capability or have reduced their debt levels can be good picks as interest rates will continue to remain high.
Investors are scrambling to purchase shares in drug and condom maker, Mankind Pharma Ltd., which has had the most analyst coverage of any new Indian stock in 12 years after its highly successful May IPO. The shares have surged by 57% since being listed, driving its market value above $8bn. The firm has attracted nine buy ratings and one hold. While the majority of analysts recommend buying shares, the consensus price target is already 10% below the current value due to its stellar run.